Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).

Abstract

Vismodegib (GDC-0449, Genentech, USA), a small molecule inhibitor of the Hedgehog signalling pathway, has potent anti-tumour activity in advanced basal cell carcinoma (BCC). We report a case of a 67-year-old Australian man with metastatic BCC including pulmonary disease with malignant effusion who showed a dramatic complete response to vismodegib but subsequently experienced a recurrence of pulmonary disease, indicative of chemoresistance to vismodegib. This case is the first to illustrate chemoresistance in a patient with metastatic BCC, and demonstrates the need for closely monitoring metastatic BCC patients even after an apparently complete response.

• Authors: Rowena E Meani, Shueh-Wen Lim, Anne Lynn S Chang, John W Kelly
• Journal: The Australasian journal of dermatology (Australas J Dermatol) Vol. 55 Issue 3 Pg. 218-21 (Aug 2014) ISSN: 1440-0960 [Electronic] Australia
• PMID: 25117162 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2014 The Australasian College of Dermatologists.

Chemical References

• Anilides
• Antineoplastic Agents
• Hedgehog Proteins
• HhAntag691
• Pyridines

Topics

• Aged
• Anilides (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Bone Neoplasms (drug therapy, secondary)
• Carcinoma, Basal Cell (drug therapy, secondary)
• Drug Resistance, Neoplasm
• Hedgehog Proteins (antagonists & inhibitors)
• Humans
• Lung Neoplasms (drug therapy, secondary)
• Lymphatic Metastasis
• Male
• Pyridines (therapeutic use)
• Ribs
• Signal Transduction (drug effects)
• Skin Neoplasms (drug therapy, pathology)